Evidence map›Paper›PMID 16235327›Full record

SynthesisThe Cochrane database of systematic reviews2005

Cardioselective beta-blockers for chronic obstructive pulmonary disease.

S Salpeter, T Ormiston, E Salpeter

Registry-linked trialOpen access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03566667 (Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE), which is not on this map. Cited by 113 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 11 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03566667 phase4completednot on this mapstarted 2018, after this paper: background citation

Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE

TypeinterventionalSponsorOle Frobert, MD, PhDRan2018 to 2026Enrolled1,713ConditionsChronic Obstructive Pulmonary DiseaseArmsMetoprolol, Standard care
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 11 syntheses or guidelines pooled it, 380 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Metoprolol for the Prevention of Acute Exacerbations of COPD.The New England journal of medicine · 2019
    Trial
  18. Trial
  19. Survival With β-Adrenergic Suppression After Lung Transplantation.Journal of the American Heart Association · 2026
    Observational
  20. Appraisal of β-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

S SalpeterStanford University, and Santa Clara Valley Medical Center, Medicine, 2400 Moorpark Ave, Suite 118, San Jose, CA 95128, USA. shelley.salpeter@hhs.co.santa-clara.ca.us
T Ormiston
E Salpeter
Cornell University · USSanta Clara Valley Medical Center · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeta-blocker therapy has a proven mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the perioperative period. These drugs have traditionally been considered contraindicated in patients with chronic obstructive pulmonary disease (COPD).

objectivesTo assess the effect of cardioselective beta-blockers on respiratory function of patients with COPD. SEARCH STRATEGY: A comprehensive search of the Cochrane Airways Group Specialised Register (derived from systematic searches of CENTRAL, MEDLINE, EMBASE and CINAHL) was carried out to identify randomised blinded controlled trials from 1966 to May 2005. We did not exclude trials on the basis of language. SELECTION CRITERIA: Randomised, blinded, controlled trials of single dose or longer duration that studied the effects of cardioselective beta-blockers on the forced expiratory volume in 1 second (FEV1) or symptoms in patients with COPD. DATA COLLECTION AND ANALYSIS: Two independent reviewers extracted data from the selected articles, reconciling differences by consensus. Two interventions studied were the administration of beta-blocker, given either as a single dose or for longer duration, and the use of beta2-agonist given after the study drug. MAIN

resultsEleven studies of single-dose treatment and 9 of treatment for longer durations, ranging from 2 days to 12 weeks, met selection criteria. Cardioselective beta-blockers, given as a single dose or for longer duration, produced no change in FEV1 or respiratory symptoms compared to placebo, and did not affect the FEV1 treatment response to beta2-agonists. A subgroup analysis revealed no change in results for those participants with severe chronic airways obstruction or for those with a reversible obstructive component. AUTHORS'

conclusionsCardioselective beta-blockers, given to patients with COPD in the identified studies did not produce adverse respiratory effects. Given their demonstrated benefit in conditions such as heart failure, coronary artery disease and hypertension, cardioselective beta-blockers should not be routinely withheld from patients with COPD.

Indexed as

Adrenergic beta-AntagonistsForced Expiratory VolumeHumansPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicAdrenergic beta-Antagonists

Identifiers

PMID16235327
PMCPMC8719355
OpenAlexW1960263711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.